Magazine Article | December 1, 2021

What's The Biopharma Financial View For 2022?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

If we thought investment in the biopharmaceutical industry was hot last year, then 2021 proved downright volcanic. Not only did we see plenty of “traditional” IPOs, but the special purpose acquisition corporation (SPAC) route that came into favor in 2020 also seemed to gain momentum. But the world of biopharmaceutical finance is more than what happens in the markets. For example, initiatives to halt climate change have executives reconsidering how their companies conduct business in striving for a net-zero carbon footprint. Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader